One might speculate that blocking antibodies to ECP could be a symptom relieving addition to the already established GC and anti-IL5 therapies used in eosinophil rich asthma and other eosinophilic diseases [113, 151, 152]. This evidence concerns the gene IL5 and eosinophil disorder.